Goldman downgrades key defense stocks to sell
CNBC’s Morgan Brennan joins ‘Power Lunch’ to report on Goldman Sachs’ sweeping downgrade of key stocks in the defense sector.
03:57
Fri, Jan 13 20232:43 PM EST
Similar Posts
Here’s why cash still dominates even though the risk of spreading coronavirus encourages contactless options
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Coronavirus has caused an unprecedented surge in the demand for contactless payment, but the U.S. is unlikely to stop using cash anytime soon. 14:13 Wed, Dec 2 20202:53 PM EST
Nasdaq CEO: 2023 IPOs performing well should give investors a ‘boost of confidence’
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Adena Friedman, Nasdaq CEO, joins ‘Closing Bell Overtime’ to talk possible IPOs in 2024, market volatility, AI investing and more. 05:04 Wed, Jan 10 20245:28 PM EST
Watch CNBC’s full interview with Trivariate Research’s Adam Parker and Wealth Enhancement’s Nicole Webb
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Trivariate Research CEO Adam Parker and Nicole Webb, senior vice president and financial advisor at Wealth Enhancement Group, join ‘Closing Bell’ to discuss their market outlook for 2024, expectations from the Fed, and more. 19:36 Tue, Jan 9 20243:35 PM EST
Behind the Scenes: Suze
Suze Orman offers a behind the scenes look at her show.
Jim Cramer recaps the year in generative artificial intelligence
CNBC’s Jim Cramer looked back on the year of artificial intelligence and highlighted some ways it has affected the world. “The good news? Generative AI can’t do everything,” Cramer said on his Thursday show. “The bad news? What it can do, it does better than we’ll ever do, unless maybe you’re Einstein or Beethoven or…
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
